Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

A NADH Oxidase Nanozyme Restores Redox Homeostasis to Ameliorate Multi-Organ Aging and Ischemic Cardiomyopathy.

Chen Y., Liang Y., Shen J., Wang Y., Qiu B., Hou H.

Laboratory Study on Cardiovascular Disease, published in Research (Wash D C) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Research (Wash D C) (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41164431
PMCID
PMC12559800
DOI
10.34133/research.0973
Citations
2

Abstract (original English)

Redox imbalance resulting from NAD + [nicotinamide adenine dinucleotide (oxidized form)] depletion and NADH (reduced form of NAD + ) accumulation is a conserved hallmark of both aging and myocardial infarction (MI), promoting cellular senescence and limiting the efficacy of regenerative therapies. Despite several NADH oxidase (NOX)-mimetic nanozymes having been reported, their therapeutic utility in aging and cardiovascular repair remains largely unexplored. Here, we present a vanadium-based nanozyme (MXene-TA) that mimics bacterial NOX activity, catalytically oxidizing NADH to restore NAD + and directly fixing redox imbalance. In aged (24-month-old) mice, systemic MXene-TA administration restored NAD + /NADH homeostasis and reduced senescence markers (p16, p21, γH2AX, and SASP) in the heart, liver, and spleen, yet this effect was not observed in the lungs or kidneys, indicating organ-specific redox susceptibility. In a rat MI model, local injection of MXene-TA into the infarcted myocardium reprogrammed metabolism, activated NAD + -dependent pathways, attenuated oxidative damage in cardiomyocytes, decreased infarct area, and enhanced myocardial function. To further enhance stem cell retention and function, we embedded MXene-TA and adipose-derived stem cells (ADSCs) into a pH-responsive, conductive hydrogel that mimics cardiac mechanical and electrical properties. This platform

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research